Literature DB >> 24928650

Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs.

Ambrosia Garcia1, Sarah Keinonen1, Ana M Sanchez1, Guido Ferrari2, Thomas N Denny3, M Anthony Moody4.   

Abstract

External proficiency testing programs designed to evaluate the performance of end-point laboratories involved in vaccine and therapeutic clinical trials form an important part of clinical trial quality assurance. Good clinical laboratory practice (GCLP) guidelines recommend both assay validation and proficiency testing for assays being used in clinical trials, and such testing is facilitated by the availability of large numbers of well-characterized test samples. These samples can be distributed to laboratories participating in these programs and allow monitoring of laboratory performance over time and among participating sites when results are obtained with samples derived from a large master set. The leukapheresis procedure provides an ideal way to collect samples from participants that can meet the required number of cells to support these activities. The collection and processing of leukapheresis samples require tight coordination between the clinical and laboratory teams to collect, process, and cryopreserve large number of samples within the established ideal time of ≤8 hours. Here, we describe our experience with a leukapheresis cryopreseration program that has been able to preserve the functionality of cellular subsets and that provides the sample numbers necessary to run an external proficiency testing program.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Leukapheresis; Leukocytes; PBMC; Proficiency testing

Mesh:

Year:  2014        PMID: 24928650      PMCID: PMC4138237          DOI: 10.1016/j.jim.2014.05.019

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

1.  Variation in protein levels obtained from human blood cells and biofluids for platelet, peripheral blood mononuclear cell, plasma, urine and saliva proteomics.

Authors:  L Katie Crosley; Susan J Duthie; Abigael C Polley; Freek G Bouwman; Carolin Heim; Francis Mulholland; Graham Horgan; Ian T Johnson; Edwin C Mariman; Ruan M Elliott; Hannelore Daniel; Baukje de Roos
Journal:  Genes Nutr       Date:  2009-04-29       Impact factor: 5.523

Review 2.  Hyperleukocytosis, leukostasis and leukapheresis: practice management.

Authors:  Chezi Ganzel; Joanne Becker; Paul D Mintz; Hillard M Lazarus; Jacob M Rowe
Journal:  Blood Rev       Date:  2012-02-23       Impact factor: 8.250

3.  Leukocyte and platelet collection from normal donors with the continuous flow blood cell separator.

Authors:  R G Graw; G P Herzig; R J Eisel; S Perry
Journal:  Transfusion       Date:  1971 Mar-Apr       Impact factor: 3.157

4.  Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays.

Authors:  Adriana Weinberg; Lin Ye Song; Cindy L Wilkening; Terry Fenton; John Hural; Raul Louzao; Guido Ferrari; Paige E Etter; Mark Berrong; Jennifer D Canniff; Donald Carter; Olivier D Defawe; Ambrosia Garcia; Tania L Garrelts; Rebecca Gelman; Linda K Lambrecht; Savita Pahwa; Sudheesh Pilakka-Kanthikeel; David L Shugarts; Nancy B Tustin
Journal:  J Immunol Methods       Date:  2010-10-01       Impact factor: 2.303

5.  Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials.

Authors:  Marta Bull; Deborah Lee; Jason Stucky; Ya-Lin Chiu; Abbe Rubin; Helen Horton; M Juliana McElrath
Journal:  J Immunol Methods       Date:  2007-02-28       Impact factor: 2.303

6.  Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials.

Authors:  Marcella Sarzotti-Kelsoe; Josephine Cox; Naana Cleland; Thomas Denny; John Hural; Leila Needham; Daniel Ozaki; Isaac R Rodriguez-Chavez; Gwynneth Stevens; Timothy Stiles; Tony Tarragona-Fiol; Anita Simkins
Journal:  PLoS Med       Date:  2009-05-05       Impact factor: 11.069

  6 in total
  13 in total

1.  Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8+ T Cell Responses with Antitumor Activity.

Authors:  Matthew G Booty; Kelan A Hlavaty; Adam Stockmann; Emrah Ilker Ozay; Carolyne Smith; Lina Tian; Edylle How; Disha Subramanya; Anita Venkitaraman; Christian Yee; Olivia Pryor; Kelly Volk; Katarina Blagovic; Ildefonso Vicente-Suarez; Defne Yarar; Melissa Myint; Amy Merino; Jonathan Chow; Tarek Abdeljawad; Harry An; Sophia Liu; Shirley Mao; Megan Heimann; LeeAnn Talarico; Miye K Jacques; Eritza Chong; Lucas Pomerance; John T Gonzalez; Ulrich H von Andrian; Klavs F Jensen; Robert Langer; Hendrik Knoetgen; Christine Trumpfheller; Pablo Umaña; Howard Bernstein; Armon Sharei; Scott M Loughhead
Journal:  J Immunol       Date:  2022-01-28       Impact factor: 5.426

2.  Toward development of a comprehensive external quality assurance program for polyfunctional intracellular cytokine staining assays.

Authors:  Janet S Staats; Jennifer H Enzor; Ana M Sanchez; Wes Rountree; Cliburn Chan; Maria Jaimes; Ray Chun-Fai Chan; Amitabh Gaur; Thomas N Denny; Kent J Weinhold
Journal:  J Immunol Methods       Date:  2014-06-23       Impact factor: 2.303

3.  Introduction to a Special Issue of the Journal of Immunological Methods: Building global resource programs to support HIV/AIDS clinical trial studies.

Authors:  Ana M Sanchez; Thomas N Denny; Maurice O'Gorman
Journal:  J Immunol Methods       Date:  2014-06-06       Impact factor: 2.303

4.  The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells.

Authors:  Marcella Sarzotti-Kelsoe; Leila K Needham; Wes Rountree; John Bainbridge; Clive M Gray; Susan A Fiscus; Guido Ferrari; Wendy S Stevens; Susan L Stager; Whitney Binz; Raul Louzao; Kristy O Long; Pauline Mokgotho; Niranjini Moodley; Melanie Mackay; Melissa Kerkau; Takesha McMillion; Jennifer Kirchherr; Kelly A Soderberg; Barton F Haynes; Thomas N Denny
Journal:  J Immunol Methods       Date:  2014-06-05       Impact factor: 2.303

5.  SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques.

Authors:  Amir Dashti; Chevaughn Waller; Maud Mavigner; Nils Schoof; Katharine J Bar; George M Shaw; Thomas H Vanderford; Shan Liang; Jeffrey D Lifson; Richard M Dunham; Guido Ferrari; Marina Tuyishime; Chia-Ying K Lam; Jeffrey L Nordstrom; David M Margolis; Guido Silvestri; Ann Chahroudi
Journal:  J Virol       Date:  2020-10-14       Impact factor: 5.103

6.  Impaired circulating myeloid CD1c+ dendritic cell function in human glioblastoma is restored by p38 inhibition - implications for the next generation of DC vaccines.

Authors:  Jason Adhikaree; Hester Ann Franks; Constantinos Televantos; Poonam Vaghela; Aanchal Preet Kaur; David Walker; Marc Schmitz; Andrew Mark Jackson; Poulam Manubhai Patel
Journal:  Oncoimmunology       Date:  2019-04-13       Impact factor: 8.110

7.  A multivariate, quantitative assay that disentangles key kinetic parameters of primary human T cell function in vitro.

Authors:  Grace L Huang; Daniel P Nampe; Jason Yi; Grant B Gabrelow; Kathleen R Negri; Alexander Kamb; Han Xu
Journal:  PLoS One       Date:  2020-11-09       Impact factor: 3.240

8.  Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection.

Authors:  Alan D Curtis; Pooja T Saha; Maria Dennis; Stella J Berendam; Pratamesh Ramasubramanian; Kaitlyn A Cross; S Munir Alam; Guido Ferrari; Pamela A Kozlowski; Genevieve G Fouda; Michael G Hudgens; Koen K A Van Rompay; Justin Pollara; Sallie R Permar; Kristina De Paris
Journal:  mSphere       Date:  2022-02-23       Impact factor: 4.389

9.  Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules.

Authors:  Justin Pollara; R Whitney Edwards; Shalini Jha; Chia-Ying Kao Lam; Liqin Liu; Gundo Diedrich; Jeffrey L Nordstrom; Tori Huffman; Joy A Pickeral; Thomas N Denny; Sallie R Permar; Guido Ferrari
Journal:  Front Immunol       Date:  2020-04-21       Impact factor: 7.561

10.  Re-examination of MAGE-A3 as a T-cell Therapeutic Target.

Authors:  Aaron D Martin; Xueyin Wang; Mark L Sandberg; Kathleen R Negri; Ming L Wu; Dora Toledo Warshaviak; Grant B Gabrelow; Michele E McElvain; Bella Lee; Mark E Daris; Han Xu; Alexander Kamb
Journal:  J Immunother       Date:  2021-04-01       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.